Laffont F, Mayer G, Minz M
Unité de Sommeil, Explorations Fonctionnelles Neurologiques, CHU Pitié-Salpêtrière, Paris, France.
Sleep. 1994 Dec;17(8 Suppl):S113-5. doi: 10.1093/sleep/17.suppl_8.s113.
The efficacy of modafinil, a psychostimulant drug acting on postsynaptic alpha-1 adrenergic receptors, as a treatment for excessive daytime sleepiness was studied in 123 patients. Subjects included 94 narcoleptic patients (76 with cataplexy), 23 hypersomnia patients and 6 patients with disrupted nocturnal sleep (DNS) and excessive daytime sleepiness (EDS). Clinical efficacy of the treatment on each symptom (EDS, cataplexy and DNS) was evaluated on a four-point scale from excellent to absent. The effectiveness of modafinil as a treatment for EDS was excellent in 17% of all patients, good in 63%, fair in 17% and absent in 3%. The incidence of side effects was rather low (14 of 123 patients) and most of them disappeared (11 patients) when doses were reduced.
对123例患者研究了莫达非尼（一种作用于突触后α-1肾上腺素能受体的精神兴奋药物）治疗日间过度嗜睡的疗效。研究对象包括94例发作性睡病患者（76例有猝倒症）、23例特发性嗜睡症患者以及6例夜间睡眠中断（DNS）且伴有日间过度嗜睡（EDS）的患者。根据从极佳到无改善的四点量表评估该治疗对每种症状（EDS、猝倒症和DNS）的临床疗效。莫达非尼治疗EDS的有效性在所有患者中极佳的占17%，良好的占63%，中等的占17%，无效的占3%。副作用发生率相当低（123例患者中有14例），且大多数副作用在降低剂量时消失（11例患者）。
